Key result
ATP-MgCl2 decreased mean pulmonary artery pressure by 24% (P<.05) and pulmonary vascular resistance index by 47% (P<.05), with effects comparable to tolazoline but without significant side effects.
Why the study?
Does ATP-MgCl2 reduce pulmonary artery pressure and vascular resistance in children with pulmonary hypertension secondary to congenital heart defects?
Population
35 children with pulmonary hypertension secondary to congenital heart defects
Comparison
ATP-MgCl2 administered intravenously vs Tolazoline in the cardiac catheterization group
Design
Cohort
Authors
Loading...
May warrant consideration as pulmonary vasodilator in pediatric CHD-PH; extends observational data but leaves open randomized confirmation.
Does ATP-MgCl2 reduce pulmonary artery pressure and vascular resistance in children with pulmonary hypertension secondary to congenital heart defects?
p-value: p=<.05
ATP-MgCl2 is a safe and effective preferential pulmonary vasodilator for evaluating and treating pulmonary hypertension in children with congenital heart defects.
Brook et al. (1994) studied Pulmonary hypertension secondary to congenital heart defects (n=35). ATP-MgCl2 vs. Tolazoline (1 mg/kg) was evaluated on Mean pulmonary artery pressure (PAP) (p=<.05). ATP-MgCl2 decreased mean pulmonary artery pressure by 24% (P<.05) and pulmonary vascular resistance index by 47% (P<.05), with effects comparable to tolazoline but without significant side effects.